{
  "signal_id": "SIG-2026-020",
  "observed_date": "2026-02-24",
  "category": "Healthspan Therapeutics",
  "title": "PROSPR funds GPER agonist development to test improvement in aging outcomes",
  "what_changed": "ARPA-H awarded Linnaeus Therapeutics up to $21.9 million to test whether a once-daily GPER agonist with an established safety profile and cardiometabolic benefits improves aging outcomes.",
  "why_it_matters": "This adds another concrete therapeutic path inside the federal healthspan portfolio and helps define what kinds of interventions and outcomes PROSPR will test.",
  "affected_actors": [
    "ARPA-H",
    "Linnaeus Therapeutics",
    "researchers",
    "regulators",
    "healthspan industry"
  ],
  "decision_implication": "Track outcome selection, human trial design, safety, biomarker changes, and whether results support broader healthspan claims.",
  "status": "Active R&D",
  "evidence_class": "E5 — official ARPA-H source",
  "impact": 4,
  "immediacy": 3,
  "relevance": 5,
  "novelty": 4,
  "adoption_leverage": 4,
  "priority_score": 81,
  "sources": [
    "https://arpa-h.gov/explore-funding/awards/4196"
  ],
  "public_slug": "/signal/2026-02-24-prospr-gper/",
  "watch_conditions": [
    "Trial start",
    "endpoints",
    "safety",
    "efficacy",
    "regulatory engagement."
  ],
  "last_verified": "2026-08-08",
  "version": "1.0"
}